Aflibercept Ophthalmic Dosage

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Macular Degeneration

Neovascular (Wet) Age Related Macular Degeneration (AMD):
2 mg (0.05 mL) administered by intravitreal injection every 4 weeks (monthly) for the first 12 weeks (3 months), followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks (2 months).

Comments: Additional efficacy was not demonstrated when dosed every 4 weeks compared to every 8 weeks.

Usual Adult Dose for Macular Edema

Macular edema following central retinal vein occlusion (CRVO):
2 mg (0.05 mL) administered by intravitreal injection once every 4 weeks (monthly).

Diabetic Macular Edema (DME):
2 mg (0.05 mL) administered by intravitreal injection every 4 weeks (monthly) for the first 5 injections, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks (2 months).

Comments: Additional efficacy was not demonstrated when dosed every 4 weeks compared to every 8 weeks.

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

No adjustment recommended.

Precautions

Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).

Dialysis

Data not available

Other Comments

Reconstitution/preparation techniques:
-Refer to the manufacturer product information for preparation instructions.
-The product should be inspected visually prior to administration. If particulates, cloudiness, or discoloration are visible, the vial should not be used.
- The intravitreal injection procedure should be carried out under controlled aseptic conditions, which include surgical hand disinfection and the use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a topical broad-spectrum microbicide should be given prior to the injection.
-Immediately following the intravitreal injection, patients should be monitored for elevation in intraocular pressure. Appropriate monitoring may consist of a check for perfusion of the optic nerve head or tonometry. If required, a sterile paracentesis needle should be available.
-Following intravitreal injection, patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment (e.g., eye pain, redness of the eye, photophobia, blurring of vision).
-Each vial should only be used for the treatment of a single eye. If the contralateral eye requires treatment, a new vial should be used. -After injection, any unused product should be discarded.

Patient advice:
-In the days following administration, patients are at risk of developing endophthalmitis or retinal detachment. If the eye becomes red, sensitive to light, painful, or develops a change in vision, patients should seek immediate care from an ophthalmologist.
-Patients may experience temporary visual disturbances after an intravitreal injection and the associated eye examinations. Patients should be advised not to drive or use machinery until visual function has recovered sufficiently.
-Intravitreal aflibercept has minor influence on the ability to drive and use machines due to possible temporary visual disturbances. Patients should not drive or use machines until their visual function has recovered sufficiently.

Hide
(web5)